Which has stronger valuation & earnings, AURA or ELVN?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aura Biosciences N/A N/A -$106.19M -$1.74 N/A Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A

Is AURA or ELVN more profitable?

Enliven Therapeutics' return on equity of -21.04% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% Enliven Therapeutics N/A -21.04% -20.41%

Does the media favor AURA or ELVN?

In the previous week, Enliven Therapeutics had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 4 mentions for Enliven Therapeutics and 1 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of -0.04 beat Enliven Therapeutics' score of -0.53 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enliven Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media prefer AURA or RARE?

In the previous week, Ultragenyx Pharmaceutical had 11 more articles in the media than Aura Biosciences. MarketBeat recorded 12 mentions for Ultragenyx Pharmaceutical and 1 mentions for Aura Biosciences. Ultragenyx Pharmaceutical's average media sentiment score of 1.25 beat Aura Biosciences' score of -0.04 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, AURA or VERA?

Vera Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aura Biosciences N/A N/A -$106.19M -$1.74 N/A Vera Therapeutics N/A N/A -$299.61M -$5.54 N/A

Is AURA or VERA more profitable?

Vera Therapeutics' return on equity of -74.86% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% Vera Therapeutics N/A -74.86% -60.18%

Does the media favor AURA or VERA?

In the previous week, Vera Therapeutics had 2 more articles in the media than Aura Biosciences. MarketBeat recorded 3 mentions for Vera Therapeutics and 1 mentions for Aura Biosciences. Vera Therapeutics' average media sentiment score of 0.87 beat Aura Biosciences' score of -0.04 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vera Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, AURA or KLRA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aura Biosciences N/A N/A -$106.19M -$1.74 N/A Kailera Therapeutics N/A N/A N/A N/A N/A

Is AURA or KLRA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% Kailera Therapeutics N/A N/A N/A

Do analysts prefer AURA or NNNN?

Aura Biosciences presently has a consensus target price of $20.50, suggesting a potential upside of 192.02%. Given Aura Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Aura Biosciences is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aura Biosciences 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, AURA or NNNN?

Anbio Biotechnology has higher revenue and earnings than Aura Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aura Biosciences N/A N/A -$106.19M -$1.74 N/A Anbio Biotechnology $8.65M 261.16 $6.40M N/A N/A

Is AURA or NNNN more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% Anbio Biotechnology N/A N/A N/A

Does the media favor AURA or NNNN?

In the previous week, Aura Biosciences and Aura Biosciences both had 1 articles in the media. Anbio Biotechnology's average media sentiment score of 0.76 beat Aura Biosciences' score of -0.04 indicating that Anbio Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anbio Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aura Biosciences (AURA) Competitors

$7.02 +0.07 (+1.01%)

As of 06/23/2026 04:00 PM Eastern

Compare

AURA vs. ELVN, RARE, VERA, KLRA, and NNNN

Should you buy Aura Biosciences stock or one of its competitors? MarketBeat compares Aura Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aura Biosciences include Enliven Therapeutics (ELVN), Ultragenyx Pharmaceutical (RARE), Vera Therapeutics (VERA), Kailera Therapeutics (KLRA), and Anbio Biotechnology (NNNN). These companies are all part of the "pharmaceutical products" industry.

How does Aura Biosciences compare to Enliven Therapeutics?

Aura Biosciences (NASDAQ:AURA) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 6.3% of Aura Biosciences shares are owned by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Enliven Therapeutics had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 4 mentions for Enliven Therapeutics and 1 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of -0.04 beat Enliven Therapeutics' score of -0.53 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enliven Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Aura Biosciences has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

Aura Biosciences presently has a consensus target price of $20.50, suggesting a potential upside of 192.02%. Enliven Therapeutics has a consensus target price of $63.40, suggesting a potential upside of 30.45%. Given Aura Biosciences' higher probable upside, equities research analysts plainly believe Aura Biosciences is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Enliven Therapeutics' return on equity of -21.04% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Enliven Therapeutics	N/A	-21.04%	-20.41%

Summary

Enliven Therapeutics beats Aura Biosciences on 8 of the 14 factors compared between the two stocks.

How does Aura Biosciences compare to Ultragenyx Pharmaceutical?

Aura Biosciences (NASDAQ:AURA) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Aura Biosciences has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 6.3% of Aura Biosciences shares are owned by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aura Biosciences has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Aura Biosciences' return on equity of -78.12% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

In the previous week, Ultragenyx Pharmaceutical had 11 more articles in the media than Aura Biosciences. MarketBeat recorded 12 mentions for Ultragenyx Pharmaceutical and 1 mentions for Aura Biosciences. Ultragenyx Pharmaceutical's average media sentiment score of 1.25 beat Aura Biosciences' score of -0.04 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aura Biosciences presently has a consensus price target of $20.50, suggesting a potential upside of 192.02%. Ultragenyx Pharmaceutical has a consensus price target of $59.56, suggesting a potential upside of 107.10%. Given Aura Biosciences' higher possible upside, equities research analysts plainly believe Aura Biosciences is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

Aura Biosciences has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Ultragenyx Pharmaceutical	$673M	4.21	-$575M	-$6.11	N/A

Summary

Aura Biosciences and Ultragenyx Pharmaceutical tied by winning 8 of the 16 factors compared between the two stocks.

How does Aura Biosciences compare to Vera Therapeutics?

Aura Biosciences (NASDAQ:AURA) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Aura Biosciences has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

Vera Therapeutics' return on equity of -74.86% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Vera Therapeutics	N/A	-74.86%	-60.18%

In the previous week, Vera Therapeutics had 2 more articles in the media than Aura Biosciences. MarketBeat recorded 3 mentions for Vera Therapeutics and 1 mentions for Aura Biosciences. Vera Therapeutics' average media sentiment score of 0.87 beat Aura Biosciences' score of -0.04 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vera Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vera Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 6.3% of Aura Biosciences shares are owned by company insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Aura Biosciences currently has a consensus target price of $20.50, suggesting a potential upside of 192.02%. Vera Therapeutics has a consensus target price of $78.00, suggesting a potential upside of 104.19%. Given Aura Biosciences' higher possible upside, equities research analysts clearly believe Aura Biosciences is more favorable than Vera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Vera Therapeutics beats Aura Biosciences on 9 of the 13 factors compared between the two stocks.

How does Aura Biosciences compare to Kailera Therapeutics?

Aura Biosciences (NASDAQ:AURA) and Kailera Therapeutics (NASDAQ:KLRA) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A

Aura Biosciences presently has a consensus price target of $20.50, suggesting a potential upside of 192.02%. Kailera Therapeutics has a consensus price target of $42.75, suggesting a potential upside of 100.05%. Given Aura Biosciences' higher probable upside, equities research analysts clearly believe Aura Biosciences is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

96.8% of Aura Biosciences shares are held by institutional investors. 6.3% of Aura Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Kailera Therapeutics' return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Kailera Therapeutics	N/A	N/A	N/A

In the previous week, Aura Biosciences had 1 more articles in the media than Kailera Therapeutics. MarketBeat recorded 1 mentions for Aura Biosciences and 0 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.00 beat Aura Biosciences' score of -0.04 indicating that Kailera Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aura Biosciences	Neutral
Kailera Therapeutics	Neutral

Summary

Kailera Therapeutics beats Aura Biosciences on 6 of the 10 factors compared between the two stocks.

How does Aura Biosciences compare to Anbio Biotechnology?

Aura Biosciences (NASDAQ:AURA) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Anbio Biotechnology has higher revenue and earnings than Aura Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Anbio Biotechnology	$8.65M	261.16	$6.40M	N/A	N/A

96.8% of Aura Biosciences shares are owned by institutional investors. 6.3% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Anbio Biotechnology's return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Anbio Biotechnology	N/A	N/A	N/A

Aura Biosciences presently has a consensus target price of $20.50, suggesting a potential upside of 192.02%. Given Aura Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Aura Biosciences is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Aura Biosciences and Aura Biosciences both had 1 articles in the media. Anbio Biotechnology's average media sentiment score of 0.76 beat Aura Biosciences' score of -0.04 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anbio Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aura Biosciences has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.38, indicating that its share price is 338% more volatile than the broader market.

Summary

Anbio Biotechnology beats Aura Biosciences on 6 of the 11 factors compared between the two stocks.

Get Aura Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AURA vs. The Competition

Export

Metric	Aura Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$718.54M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-4.03	19.75	24.92	23.98
Price / Sales	N/A	330.90	528.23	109.07
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	3.25	8.29	10.79	6.50
Net Income	-$106.19M	$23.85M	$3.56B	$336.88M
7 Day Performance	11.25%	2.87%	1.00%	-0.14%
1 Month Performance	-7.63%	2.19%	0.42%	0.77%
1 Year Performance	7.18%	55.48%	29.70%	28.49%

Aura Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AURA Aura Biosciences	2.5327 of 5 stars	$7.02 +1.0%	$20.50 +192.0%	+14.1%	$718.54M	N/A	N/A	50	Gap Down
ELVN Enliven Therapeutics	2.3518 of 5 stars	$42.53 +0.4%	$63.40 +49.1%	+139.5%	$2.59B	N/A	N/A	50	Insider Trade Gap Down High Trading Volume
RARE Ultragenyx Pharmaceutical	3.4083 of 5 stars	$24.82 -2.2%	$59.56 +140.0%	-21.9%	$2.44B	$673M	N/A	1,371
VERA Vera Therapeutics	3.3723 of 5 stars	$33.64 -1.8%	$78.00 +131.9%	+76.4%	$2.41B	N/A	N/A	40	Gap Down
KLRA Kailera Therapeutics	4.5517 of 5 stars	$18.53 -5.8%	$42.75 +130.7%	N/A	$2.40B	N/A	N/A	145

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AURA) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aura Biosciences (AURA) Competitors

AURA vs. ELVN, RARE, VERA, KLRA, and NNNN

How does Aura Biosciences compare to Enliven Therapeutics?

Summary

How does Aura Biosciences compare to Ultragenyx Pharmaceutical?

Summary

How does Aura Biosciences compare to Vera Therapeutics?

Summary

How does Aura Biosciences compare to Kailera Therapeutics?

Summary

How does Aura Biosciences compare to Anbio Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA vs. The Competition

Aura Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aura Biosciences (AURA) Competitors

AURA vs. ELVN, RARE, VERA, KLRA, and NNNN

How does Aura Biosciences compare to Enliven Therapeutics?

Do insiders & institutionals hold more shares of AURA or ELVN?

Does the media favor AURA or ELVN?

Which has more risk & volatility, AURA or ELVN?

Do analysts rate AURA or ELVN?

Which has stronger valuation & earnings, AURA or ELVN?

Is AURA or ELVN more profitable?

Summary

How does Aura Biosciences compare to Ultragenyx Pharmaceutical?

Which has more risk & volatility, AURA or RARE?

Do insiders and institutionals hold more shares of AURA or RARE?

Is AURA or RARE more profitable?

Does the media prefer AURA or RARE?

Do analysts recommend AURA or RARE?

Which has better earnings & valuation, AURA or RARE?

Summary

How does Aura Biosciences compare to Vera Therapeutics?

Which has more volatility & risk, AURA or VERA?

Is AURA or VERA more profitable?

Does the media favor AURA or VERA?

Which has higher valuation & earnings, AURA or VERA?

Do institutionals & insiders hold more shares of AURA or VERA?

Do analysts prefer AURA or VERA?

Summary

How does Aura Biosciences compare to Kailera Therapeutics?

Which has higher earnings & valuation, AURA or KLRA?

Do analysts rate AURA or KLRA?

Do institutionals and insiders have more ownership in AURA or KLRA?

Is AURA or KLRA more profitable?

Does the media favor AURA or KLRA?

Summary

How does Aura Biosciences compare to Anbio Biotechnology?

Which has stronger valuation and earnings, AURA or NNNN?

Do insiders and institutionals hold more shares of AURA or NNNN?

Is AURA or NNNN more profitable?

Do analysts prefer AURA or NNNN?

Does the media favor AURA or NNNN?

Which has more risk & volatility, AURA or NNNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA vs. The Competition

Aura Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools